Ashvattha Therapeutics Presents Preclinical Data on anti-VEGF Nanomedicine D-4517.2…
<!-- Name:DistributionId Value:8825608 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
ARVO
1-Year Outcomes of Phase 3 Study for SB15, Proposed biosimilar to Eylea…
<!-- Name:DistributionId Value:8823565 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Doheny Eye Institute Announces Upcoming Presentations at ARVO 2023 Annual Meeting
<!-- Name:DistributionId Value:8812683 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
DIAGNOS and ETS to Present Ground-breaking Research on Mass Screening for Macular…
<!-- Name:DistributionId Value:8749103 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
DIAGNOS et l’ÉTS présenteront une recherche novatrice sur le dépistage de masse…
<!-- Name:DistributionId Value:8749103 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell…
-- Data Demonstrate Rapid and Complete Wound Healing, with Six of Eight (75%) Patients Achieving Complete Healing within Four Weeks; All Remained Healed Through End of Follow-Up ---- All…
Graybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma at the…
BALTIMORE, April 27, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the…
Adverum Biotechnologies Announces Upcoming Data Presentations at ARVO 2022
REDWOOD CITY, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and…
Akari Therapeutics to Present on Two Ongoing Programs Covering Age-Related Macular…
NEW YORK and LONDON, March 21, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan…
Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTAC™ Therapy…
CARLSBAD, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today…